Taken together, the current investigation indicates that individualized testing for ADORA2A levels, as well as for co-expressed immunomodulatory molecules, including specific checkpoints, may be required in order to optimize precision immunotherapy-based treatment selection, in the same way that tumor genomic sequencing is needed for selecting gene-targeted treatments as part of the precision genomics paradigm [32,33]. The gene discussed is ADORA2A; the disease is neoplasm.